Literature DB >> 28618867

Human Articular Chondrocytes Induce Interleukin-2 Nonresponsiveness to Allogeneic Lymphocytes.

Satomi Abe1, Hitoshi Nochi1, Hiroshi Ito1.   

Abstract

Introduction We previously showed that articular chondrocytes (ACs) have immune privilege and immunomodulatory functions like those of mesenchymal stem cells. To elucidate these mechanisms, we focused on interleukin-2 (IL-2), which plays critical roles in lymphocyte mitogenic activity. The purpose of this study was to explore whether ACs affect the role of IL-2 underlying immunomodulatory functions. Material and Methods Irradiated human ACs from osteoarthritis donors were used. Third-party ACs were added to the mixed lymphocyte reaction (MLR) with or without recombinant human IL-2 (rhIL-2), and the levels of IL-2 and the soluble form of the IL-2 receptor α (sIL-2Rα) protein in supernatant were measured by enzyme-linked immunosorbent assay. Recombinant human IL-2 (rhIL-2) was also added to the MLR. To detect the expression of IL-2 receptor α (CD25) on lymphocytes in the MLR, flow cytometric analysis was performed. Last, ACs and allogeneic activated CD4+ T cell were co-cultured, and the expression of CD25 on activated T cells was examined by flow cytometry. Results Third-party ACs significantly inhibited the MLR and reduced the level of sIL-2Rα in a dose-dependent manner, but did not affect the concentration of IL-2. Exogenous rhIL-2 accelerated MLR but did not rescue the inhibitory effect of ACs. ACs inhibited the expression of CD25 on activated CD4+ T cells. Discussion Our results showed that third-party ACs inhibited the proliferation of allogeneic activated lymphocytes, thereby inhibiting production sIL-2Rα, although ACs did not affect IL-2 secretion from lymphocytes. Also, ACs inhibited CD25 expression on activated CD4+ T cells. Thus, ACs inhibited the immune response of allogeneic lymphocytes by inducing IL-2 nonresponsiveness.

Entities:  

Keywords:  allograft; articular cartilage; chondrocytes; immune privilege; interleukin 2

Year:  2016        PMID: 28618867      PMCID: PMC5625858          DOI: 10.1177/1947603516661820

Source DB:  PubMed          Journal:  Cartilage        ISSN: 1947-6035            Impact factor:   4.634


  30 in total

1.  Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex.

Authors:  K Le Blanc; L Tammik; B Sundberg; S E Haynesworth; O Ringdén
Journal:  Scand J Immunol       Date:  2003-01       Impact factor: 3.487

2.  The effect of stress and tissue fluid microenvironment on allogeneic chondrocytes in vivo and the immunological properties of engineered cartilage.

Authors:  Tun Yuan; Hongrong Luo; Jing Tan; Hongsong Fan; Xingdong Zhang
Journal:  Biomaterials       Date:  2011-06-14       Impact factor: 12.479

3.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

Review 4.  Both integrated and differential regulation of components of the IL-2/IL-2 receptor system.

Authors:  Hyoung Pyo Kim; Jean Imbert; Warren J Leonard
Journal:  Cytokine Growth Factor Rev       Date:  2006-09-05       Impact factor: 7.638

5.  Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene.

Authors:  J M Depper; W J Leonard; C Drogula; M Krönke; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

6.  Increased circulating concentrations of interleukin 2 receptor during rejection episodes in heart- or kidney-transplant recipients.

Authors:  G C Zucchelli; A Clerico; R De Maria; M Carmellini; R Di Stefano; S Masini; A Pilo; L Donato
Journal:  Clin Chem       Date:  1990-12       Impact factor: 8.327

7.  Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity.

Authors:  Ian B Copland; Muna Qayed; Marco A Garcia; Jacques Galipeau; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-03       Impact factor: 5.742

8.  Immunohistological analysis of serial biopsies taken during human renal allograft rejection. Changing profile of infiltrating cells and activation of the coagulation system.

Authors:  W W Hancock; D Gee; P De Moerloose; F R Rickles; V A Ewan; R C Atkins
Journal:  Transplantation       Date:  1985-04       Impact factor: 4.939

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

Review 10.  Interleukin 2: from immunostimulation to immunoregulation and back again.

Authors:  Martin F Bachmann; Annette Oxenius
Journal:  EMBO Rep       Date:  2007-12       Impact factor: 8.807

View more
  1 in total

Review 1.  Antigenic and immunogenic properties of chondrocytes. Implications for chondrocyte therapeutic transplantation and pathogenesis of inflammatory and degenerative joint diseases.

Authors:  Anna Osiecka-Iwan; Anna Hyc; Dorota M Radomska-Lesniewska; Adrian Rymarczyk; Piotr Skopinski
Journal:  Cent Eur J Immunol       Date:  2018-06-30       Impact factor: 2.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.